NFA
XLRN

Nationwide Fund Advisors’s Acceleron Pharma XLRN Stock Holding History

Nationwide Fund Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-51,678
Closed -$1.93M – 2529
2017
Q3 		$1.93M Buy
51,678
+26,941
+109% +$935K 0.01% 1459
2017
Q2 		$752K Buy
24,737
+2,000
+9% +$58K ﹤0.01% 1951
2017
Q1 		$602K Buy
22,737
+2,168
+11% +$57.1K ﹤0.01% 2053
2016
Q4 		$525K Sell
20,569
-982
-5% -$31.1K ﹤0.01% 2156
2016
Q3 		$780K Sell
21,551
-4,400
-17% -$146K ﹤0.01% 1933
2016
Q2 		$882K Buy
25,951
+2,077
+9% +$67.5K ﹤0.01% 1806
2016
Q1 		$630K Buy
23,874
+9,621
+68% +$280K ﹤0.01% 1967
2015
Q4 		$695K Buy
14,253
+208
+1% +$7.48K ﹤0.01% 1921
2015
Q3 		$350K Sell
14,045
-3,500
-20% -$105K ﹤0.01% 2300
2015
Q2 		$555K Buy
17,545
+5,495
+46% +$177K ﹤0.01% 2192
2015
Q1 		$459K Sell
12,050
-453
-4% -$18K ﹤0.01% 2281
2014
Q4 		$487K Sell
12,503
-153
-1% -$5.33K ﹤0.01% 2201
2014
Q3 		$383K Buy
12,656
+40
+0.3% +$1.13K ﹤0.01% 2356
2014
Q2 		$429K Buy
12,616
+7,140
+130% +$239K ﹤0.01% 2347
2014
Q1 		$189K Buy
5,476
+588
+12% +$26.5K ﹤0.01% 2506
2013
Q4 		$194K Buy
+4,888
New +$118K ﹤0.01% 2702

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Nationwide Fund Advisors's XLRN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Acceleron Pharma (XLRN) in Q4 2017, closing a stake of 51,678 shares — an estimated $1.93M sold.

Nationwide Fund Advisors first reported a position in XLRN in Q4 2013 and held it in 16 quarters. The position peaked at $1.93M in Q3 2017. 137 funds tracked by Wall St. Rank hold XLRN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Acceleron Pharma position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 51,678 Acceleron Pharma shares in Q4 2017, an estimated $1.93M.
  • Nationwide Fund Advisors first reported a position in Acceleron Pharma in Q4 2013 and held it in 16 quarters.
  • Nationwide Fund Advisors's Acceleron Pharma position peaked at $1.93M in Q3 2017.
  • 137 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.